Ken Griffin Hutchmed (China) LTD Transaction History

Citadel Advisors LLC

$550 Billion
Q2 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Hutchmed (China) LTD stock. As of the latest transaction made, Citadel Advisors LLC holds 37,411 shares of HCM stock, worth $602,691. This represents 0.0% of its overall portfolio holdings.

Number of Shares

37,411

Previous 9,900 277.89%

Holding current value

$602,691

Previous $148,000 280.41%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$11.81 - $17.72 $381,533 - $572,462	32,306 Added 632.83%	37,411 $563,000
Q1 2025 May 15, 2025	SELL	$13.09 - $16.75 $410,397 - $525,146	-31,352 Reduced 86.0%	5,105 $76,000
Q4 2024 Feb 14, 2025	BUY	$14.25 - $21.35 $264,594 - $396,426	18,568 Added 103.8%	36,457 $525,000
Q3 2024 Nov 14, 2024	SELL	$16.03 - $20.31 $91,803 - $116,315	-5,727 Reduced 24.25%	17,889 $349,000
Q2 2024 Aug 14, 2024	BUY	$16.36 - $21.78 $270,119 - $359,609	16,511 Added 232.39%	23,616 $404,000
Q1 2024 May 15, 2024	SELL	$12.08 - $18.56 $532,981 - $818,885	-44,121 Reduced 86.13%	7,105 $119,000
Q4 2023 Feb 14, 2024	BUY	$16.25 - $20.23 $715,097 - $890,241	44,006 Added 609.5%	51,226 $927,000
Q3 2023 Nov 14, 2023	SELL	$11.85 - $16.95 $224,664 - $321,355	-18,959 Reduced 72.42%	7,220 $122,000
Q2 2023 Aug 14, 2023	SELL	$10.78 - $17.73 $236,405 - $388,818	-21,930 Reduced 45.58%	26,179 $314,000
Q1 2023 May 15, 2023	SELL	$13.02 - $19.87 $2.2 Million - $3.35 Million	-168,804 Reduced 77.82%	48,109 $626,000
Q4 2022 Feb 14, 2023	BUY	$7.65 - $15.51 $1.13 Million - $2.29 Million	147,570 Added 212.81%	216,913 $3.21 Million
Q3 2022 Nov 14, 2022	BUY	$8.63 - $15.52 $598,430 - $1.08 Million	69,343 New	69,343 $614,000
Q1 2022 May 16, 2022	SELL	$15.52 - $35.65 $229,540 - $527,263	-14,790 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$28.89 - $35.33 $351,244 - $429,542	-12,158 Reduced 45.12%	14,790 $518,000
Q3 2021 Nov 15, 2021	BUY	$35.66 - $42.94 $511,007 - $615,330	14,330 Added 113.57%	26,948 $987,000
Q2 2021 Aug 16, 2021	SELL	$23.7 - $39.27 $376,213 - $623,371	-15,874 Reduced 55.71%	12,618 $495,000
Q1 2021 May 17, 2021	BUY	$27.01 - $36.8 $769,568 - $1.05 Million	28,492 New	28,492 $805,000
Q3 2020 Nov 16, 2020	SELL	$25.8 - $34.61 $1.03 Million - $1.38 Million	-39,812 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$17.65 - $28.05 $27,039 - $42,972	-1,532 Reduced 3.71%	39,812 $1.1 Million
Q1 2020 May 15, 2020	BUY	$15.19 - $29.51 $74,263 - $144,274	4,889 Added 13.41%	41,344 $738,000
Q4 2019 Feb 14, 2020	SELL	$17.17 - $25.95 $770,349 - $1.16 Million	-44,866 Reduced 55.17%	36,455 $914,000
Q3 2019 Nov 14, 2019	SELL	$17.84 - $22.69 $446 - $567	-25 Reduced 0.03%	81,321 $1.45 Million
Q2 2019 Aug 14, 2019	BUY	$22.0 - $31.78 $1.63 Million - $2.36 Million	74,317 Added 1057.29%	81,346 $1.79 Million
Q2 2018 Aug 10, 2018	SELL	$27.79 - $34.49 $73,504 - $91,226	-2,645 Reduced 27.34%	7,029 $0
Q1 2018 May 11, 2018	BUY	$28.87 - $41.13 $279,288 - $397,891	9,674 New	9,674 $286,000

Others Institutions Holding HCM

# of Institutions

Shares Held

6.07M

Call Options Held

Put Options Held

View Full List

About HUTCHMED (China) Ltd

Ticker HCM
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 172,955,008
Market Cap $2.79B
Description
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...

More about HCM

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account